Document:

EX-10.1

 Exhibit 10.1 

AGREEMENT 
 This agreement
(this “Agreement”) is made and entered into as of March 19, 2019, by and among Nevro Corp., a Delaware corporation (the “Company”), Broadfin Healthcare Master Fund, Ltd., a Cayman Islands exempted company
(“Broadfin Healthcare”), Broadfin Capital, LLC, a Delaware limited liability company (“Broadfin Capital”), and Kevin Kotler (collectively with Broadfin Healthcare and Broadfin Capital, “Broadfin”).
Each of the Company and Broadfin is referred to herein as a “Party” and, collectively, as the “Parties”. 

RECITALS 
 WHEREAS, the
Company and Broadfin have engaged in discussions regarding, among other things, the composition of the Board of Directors of the Company (the “Board”); 

WHEREAS, Broadfin nominated certain individuals for election as directors at the Company’s 2019 annual meeting of stockholders (the
“2019 Annual Meeting”); 
 WHEREAS, as of the date hereof, Broadfin beneficially owns (as determined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) 872,615 shares of the common stock, $0.001 par value per share, of the Company (the “Common
Stock”), constituting approximately 2.9% of the Common Stock issued and outstanding; 
 WHEREAS, Rami Elghandour has entered into a
Separation Agreement (the “Separation Agreement”), providing for, among other things, his irrevocable resignation as President and Chief Executive Officer of the Company and from the Board, certain compensation terms and non-disparagement and release of claims provisions with respect to the Company and Broadfin; 
 WHEREAS,
Ali Behbahani, M.D. (collectively with Mr. Elghandour, the “Resigning Directors”) has delivered a letter of resignation from the Board; 

WHEREAS, simultaneously with the execution of this Agreement, the Company has entered into an Employment Agreement with Keith Grossman,
providing for, among other things, the terms of Mr. Grossman’s employment with the Company as its President and Chief Executive Officer and a member of the Board (the “Employment Agreement”); and 

WHEREAS, the Parties jointly desire to come to an agreement with respect to the composition of the Board and certain other matters as provided
in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein,
and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties, intending to be legally bound, agree as follows: 

1. Management, Board Appointments and Related Agreements. 

(a) Management. The Company agrees that, simultaneously with the execution of this Agreement, as of the Effective Time (as defined
below), the Board and all applicable committees of the Board shall take all necessary action to (i) cause or accept the resignation of Mr. Elghandour as President and Chief Executive Officer of the Company in accordance with the Separation
Agreement and (ii) appoint Mr. Grossman as President and Chief Executive Officer of the Company in accordance with the Employment Agreement. 

 (b) Board Appointments; Board Committees; Board Chair; Board Size. 

(i) The Company agrees that, simultaneously with the execution of this Agreement, as of the Effective Time, the Board and all applicable
committees of the Board shall take all necessary actions to (A) cause or accept the resignation of each of the Resigning Directors from the Board, effective immediately, (B) increase the size of the Board from eight (8) members to
nine (9) members, (C) appoint Keith Grossman and Elizabeth H. Weatherman (collectively, the “New Class II Directors”) to the Board, each as a Class II director with a term expiring at the Company’s
2019 Annual Meeting, (D) appoint Kevin C. O’Boyle (together with the New Class II Directors, the “New Directors,” and each, a “New Director”) to the Board as a Class III director with a term
expiring at the Company’s 2020 annual meeting of stockholders (the “2020 Annual Meeting”), and (E) appoint Ms. Weatherman to serve on the Compensation Committee of the Board. The Board agrees to give the New Directors
the same due consideration for membership to any committee of the Board as any other member of the Board who qualifies as “independent” under the applicable rules and regulations of the U.S. Securities and Exchange Commission (the
“SEC”) and the New York Stock Exchange (“NYSE”). 
 (ii) The Board and the Nominating and Corporate
Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) agree to nominate and recommend (and not change such recommendation in a manner adverse to the New Class II Directors) that the
Company’s stockholders vote in favor of the New Class II Directors or, in accordance with Section 1(b)(v), a Replacement Director (as defined below, and who shall be deemed to be a “New Class II
Director” for purposes of this Agreement) for re-election at the 2019 Annual Meeting. The Company agrees to use its reasonable best efforts to cause the re-election
of the New Class II Directors to the Board at the 2019 Annual Meeting and otherwise support each New Class II Director for re-election at the 2019 Annual Meeting in a manner no less rigorous and
favorable than the manner in which the Company supports its other nominees. 
 (iii) The Company agrees that as promptly as practicable
following the 2019 Annual Meeting and the re-election of Mr. Grossman as a New Class II Director, Mr. Grossman shall be appointed to serve as the Chairman of the Board. 

(iv) The Board shall not, prior to the 2020 Annual Meeting, increase the size of the Board above nine (9) directors without
Broadfin’s prior written consent. 
 (v) If any New Director (or Replacement Director) other than Mr. Grossman is unable or
unwilling to serve as a director, resigns as a director, is removed as a director or ceases to serve as a director for any reason prior to the expiration of the Standstill Period (as defined below) and at such time Broadfin beneficially owns (as
determined under Rule 13d-3 promulgated under the Exchange Act) at least the lesser of (i) 2.5% of the Company’s then issued and outstanding Common Stock and (ii) 607,560 shares of Common Stock, Broadfin
shall have the ability to recommend a substitute person(s) in accordance with this Section 1(b)(v) (any such replacement nominee shall be referred to as a “Replacement Director”). Any Replacement Director
must (A) qualify as “independent” of the Company pursuant to NYSE listing standards, (B) have the relevant financial and business experience to be a director of the Company and (C) be reasonably acceptable to the Board. The
Nominating and Corporate Governance Committee shall make its determination and recommendation regarding whether such person meets the foregoing criteria within ten (10) business days after (1) such nominee

  
 2 

 
as a Replacement Director has submitted to the Company a fully completed copy of the Company’s standard director & officer questionnaire and (2) representatives of the Board
have conducted a customary interview of such nominee. The Company shall use its reasonable best efforts to conduct any interview(s) contemplated by this section as promptly as practicable, but in any case, assuming reasonable availability of the
nominee, within ten (10) business days after Broadfin’s submission of such nominee. In the event the Nominating and Corporate Governance Committee does not accept a person recommended by Broadfin as the Replacement Director (it being
acknowledged that the Nominating and Corporate Governance Committee cannot unreasonably withhold its approval), Broadfin shall have the right to recommend an additional substitute person(s) whose appointment shall be subject to the Nominating and
Corporate Governance Committee recommending such person in accordance with the procedures described above. Upon the recommendation of a Replacement Director nominee by the Nominating and Corporate Governance Committee, the Board shall vote on the
appointment of such Replacement Director to the Board no later than ten (10) business days after the Nominating and Corporate Governance Committee recommendation of such Replacement Director; provided, however, that if the Board
does not elect such Replacement Director to the Board (it being acknowledged that the Board cannot unreasonably withhold its approval) pursuant to this Section 1(b)(v), the Parties shall continue to follow the procedures of
this Section 1(b)(v) until a Replacement Director is elected to the Board. Upon a Replacement Director’s appointment to the Board, the Board and all applicable committees of the Board shall consider whether such
Replacement Director has the necessary qualifications to be appointed to any applicable committee of the Board of which the replaced director was a member immediately prior to such director’s resignation or removal, and shall appoint such
Replacement Director to either such committees or, if the qualifications for such committees are not met, to alternative committees of the Board. Any Replacement Director designated pursuant to this Section 1(b)(v)
replacing a New Class II Director prior to the 2019 Annual Meeting shall stand for election at the 2019 Annual Meeting together with the Company’s other nominees. 

(c) 2019 Annual Meeting. As of the Effective Time, Broadfin hereby (a) irrevocably withdraws the notice of stockholder nomination
of individuals for election as directors at the 2019 Annual Meeting submitted to the Company on March 8, 2019, and (b) irrevocably withdraws any related materials or notices submitted to the Company in connection therewith. 

(d) Additional Agreements. 

(i) Each Party will cause each of its Affiliates and Associates (each as defined below) to comply with the terms of this Agreement and will be
responsible for any breach of this Agreement by any such Affiliate or Associate. As used in this Agreement, the terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b-2 promulgated under the Exchange Act, and include all persons or entities that at any time during the term of this Agreement become Affiliates or Associates of any person or entity referred to in this Agreement.

 (ii) Upon the Effective Time, except as provided herein, Broadfin will not, and will not permit any of its Associates to, directly or
indirectly, (A) nominate or recommend for nomination any person for election at the 2019 Annual Meeting, (B) submit any proposal for consideration at, or bring any other business before, the 2019 Annual Meeting, or (C) initiate,
encourage or participate in any “vote no,” “withhold” or similar campaign with respect to the 2019 Annual Meeting. Broadfin will not publicly or privately encourage or support any other stockholder, person or entity to take any
of the actions described in this Section 1(d)(ii). 

  
 3 

 (iii) Broadfin will appear in person or by proxy at the 2019 Annual Meeting and will cause
all shares of Common Stock that it beneficially owns as of the record date for the 2019 Annual Meeting to be voted at the 2019 Annual Meeting in favor of the election of the New Class II Directors and otherwise in accordance with the
recommendations of the Board; provided, however, that in the event that Institutional Shareholder Services Inc. (“ISS”) or Glass, Lewis & Co., LLC (“Glass Lewis”) recommends otherwise with
respect to any proposals (other than the election of directors), Broadfin shall be permitted to vote in accordance with ISS’s or Glass Lewis’ recommendation; provided, further, that Broadfin shall be permitted to vote in its
sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition of all or substantially all of the assets of the Company or other business combination involving the Company requiring a vote of
stockholders of the Company. 
 (iv) The Parties agree that each New Director shall adhere to and act as necessary to be in compliance with
all Company policies generally applicable to the Company’s independent directors, including but not limited to policies related to insider trading and securities law compliance. 

2. Standstill Provisions. (a) Broadfin agrees that, from the Effective Time through the earlier of (x) the thirtieth (30th) calendar day prior
to the deadline for business to be properly brought before the 2020 Annual Meeting by stockholders pursuant to Section 2.4(ii) of the Company’s Amended and Restated Bylaws or (y) the date that is one hundred twenty (120) calendar
days prior to the first anniversary of the 2019 Annual Meeting (the “Standstill Period”), neither it nor any of its Associates will, and it will cause each of its Associates not to, directly or indirectly, in any manner: 

(i) engage in any solicitation of proxies or consents or become a “participant” in a “solicitation” (as such terms are
defined in Regulation 14A under the Exchange Act) of proxies or consents (including, without limitation, any solicitation of consents that seeks to call a special meeting of stockholders), in each case, with respect to securities of the Company;

 (ii) form, join or in any way participate in any “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with
respect to the Common Stock (other than a “group” that is comprised of all or some of the entities and persons that are signatories hereto); provided, however, that nothing herein shall limit the ability of an Affiliate of
Broadfin to join a “group” with Broadfin following the Effective Time, so long as any such Affiliate agrees to be bound by the terms and conditions of this Agreement; 

(iii) deposit any Common Stock or other voting securities of the Company in any voting trust or subject any such securities to any arrangement
or agreement with respect to the voting of any such securities, other than any such voting trust, arrangement or agreement solely among the members of Broadfin and otherwise in accordance with this Agreement; 

(iv) seek or submit, or encourage any person or entity to seek or submit, nomination(s) in furtherance of a “contested solicitation”
for the appointment, election or removal of directors with respect to the Company or seek, encourage or take any other action with respect to the appointment, election or removal of any directors (except as specifically

  
 4 

 
permitted in Section 1); provided, however, that nothing in this Agreement shall prevent Broadfin or its Associates from taking actions in furtherance of
identifying director candidates in connection with the 2020 Annual Meeting, so long as such actions do not create a public disclosure obligation for Broadfin or the Company, and are undertaken on a basis reasonably designed to be confidential and in
accordance in all material respects with Broadfin’s normal practices; 
 (v) (A) make any proposal for consideration by stockholders at
any annual or special meeting of stockholders of the Company, (B) make any offer or proposal (with or without conditions) with respect to any merger, acquisition, recapitalization, restructuring, disposition or other business combination
involving Broadfin or any of its Affiliates and the Company, (C) affirmatively solicit a third party, on an unsolicited basis, to make an offer or proposal (with or without conditions) with respect to any merger, acquisition, recapitalization,
restructuring, disposition or other business combination involving the Company, or publicly encourage or support any third party in making such an offer or proposal, (D) publicly comment on any third party proposal regarding any merger,
acquisition, recapitalization, restructuring, disposition, or other business combination with respect to the Company by such third party prior to such proposal becoming public, or (E) call or seek to call a special meeting of stockholders; 

(vi) seek, alone or in concert with others, representation on the Board, except as specifically permitted in
Section 1; 
 (vii) advise, encourage, support or knowingly influence any person or entity with respect to the
voting or disposition of any securities of the Company at any annual or special meeting of stockholders, except in accordance with Section 1; 

(viii) make any public proposal, alone or in concert with others, to amend any provision of the Company’s certificate of incorporation or
bylaws; 
 (ix) demand an inspection of the Company’s books and records under Section 220 of the General Corporation Law of the
State of Delaware or other statutory or regulatory provisions providing for stockholder access to books and records; or 
 (x) make any
request or submit any proposal to amend the terms of this Agreement other than through non-public communications with the Company that would not be reasonably determined to trigger public disclosure
obligations for any Party; provided that the restrictions in this Section 2(a) will terminate automatically upon the earlier of: (x) as a non-exclusive remedy for any
material breach of this Agreement (including, without limitation, any breach of Section 11), upon five (5) business days’ prior written notice by Broadfin to the Company following such breach, if such breach has
not been cured within such notice period; provided, further, that Broadfin is not in material breach of this Agreement at the time such notice is given; and (y) such time as the Company files with the SEC or delivers to its
stockholders any preliminary proxy statement, definitive proxy statement or other proxy materials in connection with the 2019 Annual Meeting that is inconsistent with the terms of this Agreement. 

(b) Except as expressly provided in Section 1 or Section 2(a), Broadfin shall be entitled
to (i) vote the Company stock that it beneficially owns as Broadfin determines in its sole discretion and (ii) disclose, publicly or otherwise, how it intends to vote or act with respect to any securities of the Company, any stockholder
proposal or other matter to be voted on by the stockholders of the Company and the reasons therefor (in each case, subject to Section 1(d)(iii)). 

  
 5 

 (c) Notwithstanding anything in Section 2(a) or elsewhere in this
Agreement, nothing in this Agreement shall prohibit or restrict Broadfin from (i) communicating privately with the Board or any of the Company’s officers regarding any matter, so long as such communications are not intended to, and would
not reasonably be expected to, require any public disclosure of such communications, (ii) communicating with stockholders of the Company and others in a manner that does not otherwise violate Section 2(a) or
Section 11, or (iii) taking any action necessary to comply with any law, rule or regulation or any action required by any governmental or regulatory authority or stock exchange that has jurisdiction over Broadfin. 

(d) Nothing in this Section 2 or elsewhere in this Agreement shall be deemed to limit the exercise in good faith by a
New Director of his or her fiduciary duties solely in his or her capacity as a director of the Company. 
 3. Representations and Warranties of the
Company. The Company represents and warrants to Broadfin that (a) the Company has the corporate power and authority to execute this Agreement and to bind it hereto, (b) this Agreement has been duly and validly authorized, executed and
delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, and (c) the execution, delivery and performance of this Agreement by the Company
does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse
of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give rise to any right of termination, amendment, acceleration or cancellation under, any
organizational document or any agreement or instrument to which the Company is a party or by which it is bound, including but not limited to giving rise to any “Change of Control” or “Change in Control” under any Company plan,
agreement or instrument. 
 4. Representations and Warranties of Broadfin. Broadfin represents and warrants to the Company that (a) Broadfin has
the corporate power and authority to execute this Agreement and to bind it hereto, (b) this Agreement has been duly and validly authorized, executed and delivered by Broadfin, constitutes a valid and binding obligation and agreement of
Broadfin, and is enforceable against Broadfin in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the
rights of creditors and subject to general equity principles, (c) the execution, delivery and performance of this Agreement by Broadfin does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree
applicable to Broadfin, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the
loss of a material benefit under, or give rise to any right of termination, amendment, acceleration or cancellation under, any organizational document or any agreement or instrument to which Broadfin is a party or by which it is bound, and
(d) as of the date of this Agreement, Broadfin beneficially owns 872,615 shares of Common Stock. 

  
 6 

 5. Press Release; Communications. Within twenty-four (24) hours following the Effective Time,
the Company and Broadfin shall jointly issue a mutually agreeable press release (the “Press Release”) announcing certain terms of this Agreement in the form attached hereto as Exhibit A. Prior to the
issuance of the Press Release and subject to the terms of this Agreement, neither the Company (including the Board and any committee thereof) nor Broadfin shall issue any press release or make any public announcement regarding this Agreement or the
matters contemplated hereby without the prior written consent of the other Party. During the Standstill Period, neither the Company nor Broadfin shall make any public announcement or statement that is inconsistent with or contrary to the terms of
this Agreement. The Company will provide Broadfin with a reasonable opportunity to review and comment on the Company’s Form 8-K disclosing this Agreement prior to its filing with the SEC and will consider
in good faith any comments received from Broadfin. 
 6. Specific Performance. Each of Broadfin, on the one hand, and the Company, on the other hand,
acknowledges and agrees that irreparable injury to the other Party hereto may occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would
not be adequately compensable by the remedies available at law (including the payment of money damages). It is accordingly agreed that Broadfin, on the one hand, and the Company, on the other hand (the “Moving Party”), shall each be
entitled to seek specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof, and the other Party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the
grounds that any other remedy or relief is available at law or in equity. This Section 6 is not the exclusive remedy for any violation of this Agreement. 

7. Expenses. The Company shall reimburse Broadfin for its reasonable and documented
out-of-pocket fees and expenses (including legal costs and expenses) incurred through the Effective Time in connection with Broadfin’s involvement at the Company,
Broadfin’s director nominations and the appointment of the New Directors to the Board, including, but not limited to the negotiation and execution of this Agreement, provided that such reimbursement shall not exceed $150,000 in the
aggregate. 
 8. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. It is hereby stipulated and declared
to be the intention of the Parties that the Parties would have executed the remaining terms, provisions, covenants and restrictions without including any of such which may be hereafter declared invalid, void or unenforceable. In addition, the
Parties agree to use their best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent jurisdiction. 

9. Notices. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement
must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally, (b) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending Party), (c) upon confirmation of receipt, 

  
 7 

 
when sent by email (provided such confirmation is not automatically generated), or (d) one (1) business day after deposit with a nationally recognized overnight delivery service, in each
case properly addressed to the Party to receive the same. The addresses and facsimile numbers for such communications shall be: 
 If to the Company: 

Nevro Corp. 
 1800 Bridge Parkway
Redwood City, California 94065 
 Attention: Kashif Rashid 

General Counsel, Corporate Secretary and Chief Compliance Officer 

Facsimile: (650) 251-0005 

E-mail: kashif.rashid@nevro.com 

with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive Menlo Park, CA 94025 

Attention:         Charles Ruck, Esq. 

                Josh Dubofsky, Esq. 

                Brian Cuneo, Esq. 

Facsimile: (650) 463-2600 

E-mail:
             charles.ruck@lw.com 

                        
  josh.dubofsky@lw.com 

                        
  brian.cuneo@lw.com 
 If to Broadfin: 

Broadfin Capital, LLC 
 300 Park
Avenue, 25th Floor 
 New York, New York 10022 

Attention: Kevin Kotler 

Facsimile: (212) 808-2464 

Email: kevin@broadfincapital.com 
 with a copy
(which shall not constitute notice) to: 
 Olshan Frome Wolosky LLP 

1325 Avenue of the Americas 
 New
York, New York 10019 
 Attention:         Steve Wolosky, Esq. 

                        
 Ryan Nebel, Esq. 
 Facsimile: (212) 451-2222 

Email:              swolosky@olshanlaw.com 

                        
 rnebel@olshanlaw.com 
 10. Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of Delaware without reference to the conflict of laws principles thereof. Each Party irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition

  
 8 

 
and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other Party hereto or its successors or assigns, shall be brought and
determined exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal court within
the State of Delaware). Each Party hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that
it will not bring any action relating to this Agreement in any court other than the aforesaid courts. Each Party hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement, (a) any claim that
it is not personally subject to the jurisdiction of the above-named courts for any reason, (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether
through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted by applicable legal requirements, any claim that (i) the
suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

 11. Mutual Non-Disparagement. Subject to applicable law, each Party covenants and agrees that, during the
Standstill Period, neither it nor any of its Affiliates, nor any of their respective principals, members, general partners, directors (or former directors, including the Resigning Directors), officers (or former officers), employees or agents shall
in any way publicly (including in any manner that could reasonably be foreseen to result in public disclosure such as statements to the press or members of the press) criticize, disparage, call into disrepute or otherwise defame or slander the other
Party or any of its Affiliates, or any of their respective principals, members, general partners, directors (or former directors, including the Resigning Directors), officers (or former officers), employees or agents, in any manner that would
reasonably be expected to damage the business or reputation thereof; provided, however, if a Party or any of its Affiliates, principals, members, general partners, directors (or former directors, including the Resigning Directors),
officers (or former officers), employees or agents shall have breached this section, then the other Party or any of its representatives may publicly respond with regards to the subject matter of such breach. The foregoing shall not restrict the
ability of any person or entity to comply with any subpoena or other legal process or respond to a request for information (provided that such request is not targeted at this Agreement or the other Party hereto) from any governmental authority with
competent jurisdiction over the party from whom information is sought. 
 12. Mutual Releases. In consideration of the mutual agreements and covenants
herein contained, as of the Effective Time, each Party knowingly and voluntarily releases and forever discharges the other Party and its Affiliates, subsidiaries, divisions, insurers, predecessors, successors and assigns, and each of their current
and former principals, members, general partners, partners, partnerships, directors (including the Resigning Directors), officers, employees, attorneys, agents and representatives (collectively, the “Released Parties”), of and from
any and all claims, known and unknown, asserted or unasserted, which any Party or its Affiliates, subsidiaries, divisions, insurers, predecessors, successors or assigns, or any of their current or former principals, members, general partners,
directors (including the Resigning Directors), officers, employees, attorneys, agents or representatives, has or may have against any Released Parties as of the date of this Agreement, including but not limited to (a) any claims, whether
statutory, common law, or otherwise, (b) any claims for breach of contract, 

  
 9 

 
breach of fiduciary duty, conversion, quantum meruit, unjust enrichment, breach of oral promise, tortuous interference with business relations, injurious falsehood, defamation, and any other
common law contract and tort claims, (c) any claims for attorneys’ fees, costs, disbursements, or other expenses, and (d) any claims for damages; provided, however, this release does not include any Party’s right to
enforce the terms of this Agreement. Nothing in this Agreement extinguishes any claims any Party may have: (i) against the other Party for breach of this Agreement or (ii) against any of the Released Parties for any claims arising from
events that occur following the date hereof. 
 13. Effectiveness. This Agreement shall become effective immediately upon the execution of this
Agreement on the date hereof (the “Effective Time”). 
 14. Entire Agreement; Amendment and Waiver; Successors and Assigns; Third Party
Beneficiaries; Term. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof. There are no restrictions, agreements, promises, representations, warranties, covenants or undertakings between the
Parties with respect to the subject matter of this Agreement other than those expressly set forth herein or in the Separation Agreement, the Employment Agreement and the other agreements contemplated thereby. No amendments or modifications of this
Agreement can be made except in writing signed by an authorized representative of each the Company and Broadfin. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are
not exclusive of any other remedies provided by law. The terms and conditions of this Agreement shall be binding upon, inure to the benefit of, and be enforceable by the Parties hereto and their respective successors, heirs, executors, legal
representatives, and permitted assigns. No Party shall assign this Agreement or any rights or obligations hereunder without, with respect to Broadfin, the prior written consent of the Company, and with respect to the Company, the prior written
consent of Broadfin. This Agreement is solely for the benefit of the Parties and is not enforceable by any other persons or entities. Unless otherwise mutually agreed in writing by each Party, this Agreement shall terminate at the end of the
Standstill Period. Notwithstanding the foregoing, the provisions of Section 6 through Section 10 and Section 12 through Section 15 shall survive
the termination of this Agreement. No termination of this Agreement shall relieve any Party from liability for any breach of this Agreement prior to such termination. 

15. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile). 

[The remainder of this page intentionally left blank] 

  
 10 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized signatories of the Parties as of the date hereof. 
  

			
	COMPANY:
	
	NEVRO CORP.
		
	By:	 	 /s/ Michael DeMane

	Name:	 	Michael DeMane
	Title:	 	Chairman of the Board of Directors
	
	BROADFIN:
	
	BROADFIN HEALTHCARE MASTER FUND, LTD.
		
	By:	 	 /s/ Kevin Kotler

	Name:	 	Kevin Kotler
	Title:	 	Director
	
	BROADFIN CAPITAL, LLC
		
	By:	 	 /s/ Kevin Kotler

	Name:	 	Kevin Kotler
	Title:	 	Managing Member
	
	KEVIN KOTLER
	
	 /s/ Kevin Kotler

 [Signature Page to Agreement] 

 EXHIBIT A 

Form of Press Release 

(see attached)slgd-ex1020_469.htm

Exhibit 10.20

 

AGREEMENT TO VARY A CONTRACT

 

This Agreement is dated March 18, 2019 and made between:

 

	
 
	
(1)
	
MONTAGNE JEUNESSE INTERNATIONAL LIMITED of The Green Barn, Astral Court, Central Avenue, Baglan Energy Park, Wales SA12 7AX

	
 
	
(2)
	
NEOTERIC COSMETICS INC of 4880 Havana Street, Suite 400, PO Box 39-S, Denver, Colorado 80239, USA

 

(together the “Parties”)

 

Background:

	
 
	
A.
	
The Parties are party to an Exclusive Distribution Agreement with an Effective date of September 15, 2014 and made between the Parties, as amended by further agreements dated April 1, 2015 and September 5, 2017 (the “Agreement”).

	
 
	
B.
	
The Parties wish to extend the termination date specified within the Agreement so that they have time to explore a new agreement which will replace the Agreement.

	
 
	
C.
	
Consequently, the parties wish to amend the Agreement as set out in this variation agreement with effect from March 14, 2019 (“Variation Date”).

 

Agreed Terms:

	
 
	
1.
	
In consideration of the mutual promises set out in this agreement, the parties agree to amend the Agreement as set out below.

	
 
	
2.
	
With effect from the Variation Date the parties agree to amend the Agreement as follows:

	
 
	
a.
	
The word "six" in the fifth line of Clause 2.1 shall be deleted and replaced with the word "three.”

 

Governing law and jurisdiction:

	
 
	
3.
	
This variation agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and interpreted in accordance with the law of England and Wales.

	
 
	
4.
	
The parties irrevocably agree that the courts of England and Wales have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) that arises out of, or in connection with, this variation agreement or its subject matter or formation.

 

 

 

			
			
	
Signed by 

DAVID LAWRENCE

for and on behalf of 

MONTAGNE JEUNESSE INTERNATIONAL LIMITED 

 
	
 
	
 

/s/ David Lawrence

Director

	
 
	
 
	
 

	
 

	
Signed by 

MARK GOLDSTEIN 

for and on behalf of 

NEOTERIC COSMETICS INC.
	
 
	
 

/s/ Mark Goldstein

President and Chief Executive Officer

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]